Publications by authors named "J C Ruiz-Carrascosa"
Psoriatic disease (PsD) affects multiple clinical domains and causes a significant inflammatory burden in patients, requiring comprehensive evaluation and treatment. In recent years, new molecules such as JAK inhibitors (JAKinhibs) have been developed. These have very clear advantages: they act quickly, have a beneficial effect on pain, are well tolerated and the administration route is oral.
View Article and Find Full Text PDFManaging moderate to severe psoriasis in older adults is complex due to factors characteristic of the later years of life, such as associated comorbidity, polypharmacy, and immunosenescence. This consensus statement discusses 17 recommendations for managing treatment for moderate to severe psoriasis in patients older than 65 years. The recommendations were proposed by a committee of 6 dermatologists who reviewed the literature.
View Article and Find Full Text PDFArticle Synopsis
- Many patients do not respond completely to biologic drugs like infliximab, adalimumab, or etanercept, and the effectiveness of these drugs can decrease over time, prompting the need for better monitoring techniques.
- A study was conducted using patient data to analyze levels of these drugs and their corresponding anti-drug antibodies, revealing a significant link between lower drug levels and treatment failure, particularly in psoriasis cases.
- The researchers proposed new therapeutic ranges for these drugs that are lower than current standards, which could enhance the ability to predict treatment success and call for more studies to validate these findings.